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Abstract
AIM: To monitor the course of continuous intraperito-
neal insulin infusion (CIPII) and to gain more insight 
into possible complications.
METHODS: A retrospective, longitudinal observational 
cohort study in patients with type 1 diabetes mellitus 
(T1DM) was performed. Only patients with “brittle” 
T1DM who started CIPII between January 1, 2000 and 
June 1, 2011, and were treated in the only centre in 
The Netherlands providing CIPII treatment (Isala clin-
ics, Zwolle) were eligible for inclusion. Outcomes were 
defined as operation-free period (OFP), rate and type 
of complications. Subanalyses were made between pa-
tients starting CIPII from 2000 to 2007 and from 2007 
onwards in order to study possible changes over time 
in complications and/or OFP. The OFP was calculated 
as the time from initial implantation to the date of first 
documented re-operation. If patients had not experi-
enced an operation, their data were recorded at the 
date of last follow up or death. Kaplan-Meier curves 
were constructed to visualize the OFP. A (two-sided) P  
value of less than 0.05 was considered statistically sig-
nificant.
RESULTS: Fifty-seven patients were treated with 
CIPII, although one patient was excluded from analy-
ses because of self-induced complications. In the re-
maining 56 patients, 70 complications occurred during 
283 patient years. Catheter occlusion (32.9%), pump 
dysfunction (17.1%), pain at the pump site (15.7%) 
and infections (10.0%) were the most frequent com-
plications. This resulted in a median OFP of 4.5 years 
(95% confidence interval 4.1-4.8 years) without any 
difference between the time periods. Fifty re-operations 
were performed because of complications, one per 5.6 
patient years, with a decrease in pump dysfunction (P  
= 0.04) and pump explantations (P  = 0.02) after 2007. 
In total, 9 episodes of ketoacidosis occurred during fol-
low up and there were 69 hospital re-admissions, with 
a median duration of 6 d. CIPII was ceased in five pa-
tients due to recurrent infections (n  = 2), pain (n  = 1), 
inadequate glycaemic control (n  = 1) or by own choice 
(n  = 1). No CIPII related mortality was reported.
CONCLUSION: The OFP has been stable over the last 
decade. No CIPII related mortality was reported. A 
significant decrease in pump dysfunction and explan-
tation was seen after 2007 compared to the period 
2000-2007. CIPII remains a safe treatment modality for 
specific patient groups. 
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INTRODUCTION
Continuous intraperitoneal insulin infusion (CIPII) with 
an implantable pump has been a treatment option for pa-
tients with diabetes since the 1980s. Nowadays this treat-
ment modality is mainly used in patients with so called 
“brittle diabetes”, i.e., failing to reach adequate glycaemic 
control despite intensive insulin therapy with multiple 
daily injections or continuous subcutaneous insulin infu-
sion and/or having frequent hypoglycaemic episodes, or 
subcutaneous insulin resistance[1,2]. 
Although the long term feasibility and positive meta-
bolic benefits of  CIPII are established by several clinical 
studies, reports on the drawbacks of  CIPII are relatively 
scarce[3,4]. Obviously, complications interfere with treat-
ment outcome with respect to glycaemic control, costs 
and, most importantly, quality of  life[5,6]. Furthermore, 
while technical problems prevented widespread use of  
CIPII in the past, modifications of  both the catheter at-
tached to the pump and the insulin have reduced the inci-
dence of  insulin aggregates blocking the insulin delivery, 
one of  the major problems in earlier years[7]. 
Haveman et al[8] underlined this development by study-
ing the complications of  CIPII in patients who started 
with CIPII before 2007 in our hospital (Isala Clinics, 
Zwolle, The Netherlands). After introduction of  a new 
battery and a change in insulin solution in 2000, the 
operation-free period (OFP) was estimated to increase 
from 21 to 78 mo. The incidence of  complications such 
as pump site infections and catheter related problems 
decreased, in accordance with other studies on CIPII[5,6]. 
However, ongoing monitoring is necessary to observe 
the course of  this decrease. Furthermore, following the 
changes in 2000 more accurate results are required on 
what the OFP really is as only a limited number of  pa-
tients had reached a 78 mo follow-up at the time of  the 
previous evaluation (follow-up until 2007). Thus it is es-
sential to extend our former study to include the period 
from 2007 onwards.
The aim of  the current study was to describe the 
complications of  CIPII in patients with type 1 diabetes 
mellitus (T1DM) over the period from 2000 until 2011. 
We also studies in detail the origin and consequences of  




In the Netherlands, the following indications for CIPII 
have been formulated: subcutaneous insulin resistance, 
brittle diabetes, hypoglycaemia unawareness, delayed in-
sulin absorption, allergies, lipohypertrophy and/or lipoat-
rophy, very lean subjects, needle phobia, severe skin scar-
ring or chronic dermatological problems[9]. Patients were 
selected for CIPII after consultation with diabetes profes-
sionals well acquainted with CIPII with, as a minimum, 
the participation of  an internist and a diabetes specialist 
nurse in the decision making. Implantation was always 
combined with intensive education and, when indicated, 
assessment by a psychologist.
All patients with T1DM who were treated with CIPII 
over the period from January 1, 2000 to June 1, 2011 were 
included in the current analysis. All of  these patients were 
referred to and treated in the Isala Clinics in Zwolle, the 
only centre in The Netherlands providing this treatment. 
For all patients, detailed clinical data regarding surgical 
placement of  the pump, short- and long-term complica-
tions and consequences were collected retrospectively by 
reviewing hospital charts, operation- and microbiology 
reports. Data were collected by use of  standardized case 
record forms.
Procedures
Insulin pump, implantation and post-operative treatment 
and refill procedures have been described previously[8]. In 
Brief, MiniMed MIP model 2007 CIPII devices (Medtron-
ic-MiniMed, Northridge, CA, United States) were im-
planted in our clinic from 2000 onwards. This model has 
a reservoir which can contains 15 mL of  a special solution 
of  U400 insulin and has a battery with 7 years longevity.
An outpatient rinse procedure with NaOH was per-
formed every 9 mo or in cases of  insulin underdelivery. 
Insulin underdelivery is present when, after the pump res-
ervoir is totally emptied, the ratio between programmed 
and actually infused volume of  programmed insulin, cal-
culated as % error, is higher than 20%. If  the % error was 
higher than 20, or a clinically significant difference be-
tween the % error calculated at previous refill was found, 
a rinse procedure was performed. In addition, inspection 
of  the patient-pump-communicator for hardware or elec-
tronic failure was performed. If  these procedures failed to 
restore normal insulin infusion a catheter flushing and/or 
catheter X-ray investigation was also performed. In case 
of  signs of  intractable occlusion despite all of  these ac-
tions, surgical examination of  the catheter to discover 
possible blockages with a post-surgical rinse of  the pump 
was deemed necessary.
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Complications
Pump-site infection was defined as a culture-proven in-
fection in the subcutaneous pocket of  the insulin pump. 
Prolonged device-related pain was defined as pain at the 
pump site which lasted for more than 6 wk after surgery 
and necessitated use of  analgesics. Cutaneous erosion of  
the skin was defined as redness with signs of  (imminent) 
perforation of  the overlying skin at the pump site. Post-
operative haematoma was defined as a swelling at the pump 
site caused by bleeding. Pump dislocation was defined as 
migration or rotation of  the pump relative to the initial 
place of  implantation. Catheter occlusion was defined as 
blockage of  the catheter by fibrin clots or an intrinsic cath-
eter defect. Encapsulation in the peritoneal cavity was de-
fined as encapsulation of  the catheter tip, positioned in the 
peritoneal cavity, by the omentum as diagnosed by catheter 
X-ray investigation or during surgical inspection. Hardware 
problems were defined as demonstrated hardware failure 
of  the pump. Premature battery end-of-life was defined as 
battery end-of-life within 3.5 years of  implantation. Pump 
dysfunction was defined as acute or chronic dysfunction 
of  the pump after excluding of  other causes e.g., battery 
end-of-life or hardware failure.
Statistical analysis
All analyses were performed using SPSS version 18.0 (Inc., 
Chicago, IL, United States). Descriptive statistics include 
number (percentage), mean ± SD and median [interquar-
tile range (IQR)]. Data were compared with the Fisher’
s exact test in the case of  categorical data. In the case of  
continuous data, Student’s t-test or Mann-Whitney U test 
were used if  the data was distributed normally or skewed, 
respectively. Q-Q plots and histograms were used to 
determine if  the tested variable had a normal distribu-
tion or not. The OFP was calculated as the time from 
initial implantation to the date of  first documented re-
operation. If  patients had not experienced an operation, 
they data were recorded at the date of  last follow up or 
time of  death. Kaplan-Meier curves were constructed to 
visualize the OFP. In order to further analyze the course 
of  the complications, subanalyses were made comparing 
patients starting CIPII from 2000 and 2007, the end of  
the previous study, and from 2007 onwards. Differences 
in time to the occurrence of  complications and the OFP 
rates were assessed for statistical significance using the 
log-rank test. A Cox regression analysis was performed 
to study the influence of  possible confounders (age, sex, 
body mass index, duration of  diabetes) on the OFP. A 
(two-sided) P value of  less than 0.05 was considered sta-
tistically significant.
RESULTS
Patients and implantation procedures
A total of  57 patients with T1DM were treated with 
CIPII. One patient with self-induced complications was 
excluded from analysis; the remaining 56 patients are sub-
ject of  this study. Patient characteristics are depicted in 
Table 1. Two hundred eighty three patient years of  follow 
up were observed, with a median duration of  4.7 years. 
In total, 80 pumps were implanted; 20 (35.7%) patients 
had a second pump and 4 (7.1%) patients had a third 
pump implanted.
Operation-free period
After starting CIPII, 33 patients underwent re-operation; 
6 because of  expected battery end-of-life, 24 because of  
complications and 3 for other reasons. As depicted in 
Figure 1, the median OFP between initial implantation 
and the first re-operation for all patients was 4.5 years 
[95% confidence interval (CI): 4.1-4.8 years]. After ex-
cluding operations for pump replacement for expected 
battery end-of-life or other reasons (n = 9) the median 
OFP was 4.5 years (95% CI: 3.9-5.0 years).
Complications
A total of  70 complications occurred during the follow-
up (Table 2). Catheter occlusion (32.9%), pump dysfunc-
tion (17.1%) and pain at the pump site (15.7%) were the 
most frequent complications. Fifty-seven complications 
occurred with the first implanted pump in situ, 11 with 
the second and 2 with the third. 21 patients did not ex-
perience any complication, 15 patients experienced 1 
complication, 11 patients 2 complications, 7 patients 3 
complications, 1 patient 4 complications, and 1 patient 8 
complications. The latter patient had recurrent infections 
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Table 1  Baseline characteristics of patients starting continuous intraperitoneal insulin infusion  n  (%)
All patients Implantation date
2000-2011 (n  = 56) 2000-2007 (n  = 37) 2007-2011 (n  = 19) 
Age (mean ± SD, yr)   37.6 ± 14.5   38.0 ± 14.4   36.6 ± 15.1
Female sex   38 (68)   28 (76)   10 (53)
Smokers      12 (21.4)        7 (18.9)        5 (26.3)
Previous abdominal operation        9 (16.1)        7 (18.9)        2 (10.5)
BMI (mean ± SD, kg/m2) 25.4 ± 4.4 26.3 ± 4.2 23.7 ± 4.3
Duration of diabetes (yr), median (IQR)         16.7 (9.7-26.3)         15.9 (9.8-26.8)         19.1 (9.6-26.3)
Retinopathy      13 (23.2)        9 (24.3)        4 (21.1)
Neuropathy      17 (30.4)      12 (32.4)        5 (26.3)
Nephropathy      4 (7.1)      3 (8.0)      1 (5.3)
BMI: Body mass index; IQR: Interquartile range.
van Dijk PR et al . Complications of continuous intraperitoneal insulin infusion
and peritonitis, after a catheter replacement procedure. 
The median time from implantation of  the first pump to 
occurrence of  the first complication (excluding battery 
end of  life) was 3.6 years (95% CI: 2.2-5.0 years).
Consequences of complications
Because of  complications, 50 re-operations were per-
formed: one per 5.6-year of  follow up (Table 3). Ex-
plantation of  the pump and catheter (34.0%, 6.0 per 100 
patient years) and catheter replacement (26.0%, 4.6 per 
100 patient years) were the most frequently performed 
re-operations. Nine episodes of  ketoacidosis occurred 
during follow up, 8 due to pump dysfunction and 1 due 
to catheter occlusion. Sixty-nine hospital re-admissions 
were caused by complications. The median duration of  
admission was 6 d (IQR: 3.0-12.8 d).
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Table 2  Complications of continuous intraperitoneal insulin infusion during follow-up
   All patients    Implantation date
   2000-2011 (n  = 56)    2000-2007 (n  = 37)    2007-2011 (n  = 19)
n  (%) Per 100 PY n  (%) Per 100 PY n  (%) Per 100 PY
Haematoma 3 (4.3)   1.1   2 (3.8)   0.9   1 (5.9)   1.8
Infection   7 (10.0)   2.5   4 (7.5)   1.8     3 (17.6)   5.3
Pain 11 (15.7)   3.9     8 (15.1)   3.5     3 (17.6)   5.3
Cutaneous erosion 2 (2.9)   0.7   2 (3.8)   0.9   0 (0.0)   0.0
Dislocation 3 (4.3)   1.1   2 (3.8)   0.9   1 (5.9)   1.8
Hardware failure 0 (0.0)   0.0   0 (0.0)   0.0   0 (0.0)   0.0
Premature battery end of life 0 (0.0)   0.0   0 (0.0)   0.0   0 (0.0)   0.0
Insulin aggregate 4 (5.7)   1.4   4 (7.5)   1.8   0 (0.0)   0.0
Catheter occlusion 23 (32.9)   8.1   16 (30.2)   7.1     7 (41.2) 12.3
Encapsulation of the catheter tip 3 (4.3)   1.1   3 (5.7)   1.3   0 (0.0)   0.0
Peritonitis 1 (1.4)   0.4   1 (1.9)   0.4   0 (0.0)   0.0
Pump dysfunction 12 (17.1)   4.2  111 (20.8)   4.9  11 (5.9)   1.8
Other 1 (1.4)   0.4   0 (0.0)   0.0   1 (5.9)   1.8
All   70 (100.0) 24.8     53 (100.0) 23.5     17 (100.0) 29.9
1P = 0.04. PY: Patient years. 
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Figure 1  Time between initial implantation and first re-operation, for all reasons (n = 56) (A) and only for complications (n = 47) (B). The dotted line repre-
sents all patients. The balck line and grey line represent patients groups who started continuous intraperitoneal insulin infusion (CIPII) between 2000 and 2007 or 
between 2007 and 2011, respectively (log rank test for differences, A: P = 0.8; B: P = 0.72). 
Course of complications
Between 2000 and 2007, 37 (median follow up 5.3 years) pa-
tients received a pump and 19 (median follow up 3.7 years) 
patients received a pump between 2007 and 2011. The 
clinical characteristics of  patients in the two different 
timeframes were comparable. Median OFP period for 
patients initially implanted between 2000 and 2007 was 
4.5 years (95% CI: 4.1-5.0 years). Only seven patients 
implanted after 2007 had a re-operation, therefore the 
median OFP could not be calculated. There were no sig-
nificant differences in median OFP (log rank: P = 0.80) 
between the two timeframes, even when excluding opera-
tions for expected battery end-of-life and reasons other 
than complications (log rank: P = 0.72) (Figure 1A and B). 
The number of  pump dysfunctions among patients 
who started CIPII after 2007 was significantly lower than 
in the group of  patients who started CIPII before 2007 
(P = 0.04) (Table 2). As depicted in Table 3, from 2007 
onwards there were significantly less re-operations for 
pump and catheter explantation following complications 
(P = 0.02). The Cox regression analysis showed a non-
significant hazard ratio of  1.12 (95% CI: 0.46-2.75, P 
= 0.52) for patients implanted after 2007 compared to 
those who were implanted between 2000 and 2007. None 
of  the confounders had a significant relation with time to 
first re-intervention.
Mortality and cessation of CIPII therapy 
During the follow up period, one patient died due to heart 
failure whilst being treated with CIPII. In 5 patients, CI-
PII was stopped and the pump removed. In two patients 
the pump was removed because of  recurrent infections 
and in the other cases because of  pain (n = 1), inadequate 
glycaemic control (n = 1) or by own choice (n = 1). The 
remaining 50 patients are still being treated with CIPII.
DISCUSSION
The current study describes the incidence of  complica-
tions in 56 patients treated with CIPII with an implanted 
insulin pump during the last decade. During 282.6 patient 
years of  follow up, 70 complications occurred, i.e., one 
complication per 4.0 patient years. Catheter occlusion 
(32.9%), pump dysfunction (17.1%), pain (15.7%) and 
infections (10.0%) were the most frequent complications. 
A significant decrease in pump dysfunction and the need 
of  premature explantation of  the pump was seen in the 
period since 2007, compared to the period before 2007. 
There was a non-significant but potentially relevant in-
crease in infections, catheter related complications and 
re-operations since 2007, although this did not affect the 
OFP during the last decade. 
In the present study we report an OFP of  4.5 years 
(95% CI: 4.1-4.8 years) among patients who started CIPII 
between 2000 and 2007. This OFP differs from the OFP 
of  6.5 years (95% CI: 2.2-10.8 years) found by Haveman 
et al[8] among a subset of  the same patients in the same 
period due to differences in follow up period. The current 
study had a longer follow up period for these patients and 
thus gives a more accurate estimate of  the OFP.
The incidence of  infections in the present study, 2.5 
per 100 patient years, is comparable to previous studies 
on CIPII and other implanted devices[5,6,8,10-13]. Appar-
ently, this rate has increased in patients operated on after 
2007 to 5.3 infections per 100 patient years. However, 
all infections appeared in one patient. Due to combined 
improvements in pump technology, insulin stability and 
frequent rinse procedures, the previously high incidence 
of  catheter blockage (between 7.8 and 57.3 per 100 pa-
tient years) has been substantially reduced[4,14-19]. In 2003, 
Gin et al[6] reported an incidence of  3.7 catheter obstruc-
tions needing surgical intervention, per 100 patient years. 
Although we found no difference in the course of  treat-
ment, compared to the limited recent literature on this 
topic, the incidence of  catheter occlusions and re-oper-
ation for catheter replacement (14.5 respectively 8.8 per 
100 patient years) since 2007 are rather high compared to 
the findings of  Gin et al[6]. 
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Table 3  Re-operations because of complications of continuous intraperitoneal insulin infusion during follow-up
    All patients     Implantation date
    2000-2011 (n  = 56)     2000-2007 (n  = 37)     2007-2011 (n  = 19)
n  (%) Per 100 PY n  (%) Per 100 PY n  (%) Per 100 PY
Catheter inspection 2 (4.0)   0.7  2 (5.3)   0.9 0 (0.0)   0.0
Catheter replacement 13 (26.0)   4.6    8 (21.1)   3.5   5 (41.7)   8.8
Explantation of pump and catheter 17 (34.0)   6.0 151 (39.5)   6.6  21 (16.7)   3.5
Repositioning of pump 2 (4.0)   0.7  2 (5.3)   0.9 0 (0.0)   0.0
Fixation of pump 2 (4.0)   0.7  1 (2.6)   0.4 1 (8.3)   1.8
Cutaneous problem 0 (0.0)   0.0  0 (0.0)   0.0 0 (0.0)   0.0
Intra-abdominal problem 1 (2.0)   0.4  1 (2.6)   0.4 0 (0.0)   0.0
Remove clot at tip of catheter/flush catheter   7 (14.0)   2.5    4 (10.5)   1.8   3 (25.0)   5.3
Haematoma 1 (2.0)   0.4  1 (2.6)   0.4 0 (0.0)   0.0
Reposition of catheter 3 (6.0)   1.1  3 (7.9)   1.3 0 (0.0)   0.0
Infection 2 (4.0)   0.7  1 (2.6)   1.2 1 (8.3)   1.8
All   50 (100.0) 17.7    38 (100.0) 44.3   12 (100.0) 21.1
1P = 0.02. PY: Patient years. 
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Besides the number of  re-operations, the impact of  
complications is illustrated by the number of  ketoacidosis 
occurrences (n = 9) and the hospital re-admissions (me-
dian duration of  6 d) following complications. DeVries 
et al[1] showed that initiation of  CIPII diminishes the me-
dian duration hospital stay for patients with poorly regu-
lated diabetes from 45 d in the year before implantation 
to 13 d in the year after implantation, the latter mostly 
due to implantation of  the pump. As far as we know, the 
present study is the first to report on the number of  hos-
pital re-admissions due to complications. This number 
would strengthen future analysis of  cost-effectiveness 
and health-related quality of  life of  CIPII.
This study has some limitations. First, since the fol-
low up of  the study performed by Haveman et al[8] ended 
at January 1, 2007 we decided to use this arbitrary point 
as cut-off  for our subanalyses for the time course of  the 
complications. Although this date is arbitrary and the 
numbers of  patients are small, it can may give insight into 
changes in complications, positively and negatively, spe-
cific for a timeframe, that would need attention for the 
present care of  these patients. Second, the exact cause of  
catheter or pump dysfunction could not always be deter-
mined and therefore the rate of  factors such as insulin 
aggregates that may have led to pump dysfunction may 
be underestimated. 
In conclusion, the median OFP for patients treated 
by CIPII with an implantable pump has been stable at 
4.5 years over the last decade. Catheter occlusion (32.9%), 
pump dysfunction (17.1%), pain at the pump site (15.7%) 
and infections (10.0%) were the most frequent complica-
tions. There was a significant decrease in the number of  
pump dysfunctions and pump explantations and no sig-
nificant alterations in the course of  complications when 
comparing the period from 2000 until 2007 and that from 
2007 onwards. However, the former group had a longer 
follow up period. This may mask a transition or possible 
future increase in complications and re-operations, thus 
suggesting a relatively stable OFP among patients. This 
will require ongoing investigation and thorough monitor-
ing over the coming years. 
Furthermore, since a new intraperitoneal insulin for-
mulation had to be introduced in June 2011 since there 
are no batches of  the original insulin formulation left, 
the findings of  the present study should be taken into ac-
count when evaluating the effects associated with the use 
of  the new insulin formulation. No CIPII related mortal-
ity was reported. CIPII remains a safe treatment modality 
for specific patient groups. 
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trol despite intensive insulin treatment with multiple daily injections or continu-
ous subcutaneous insulin infusion. The aim of the current study was to monitor 
the course and to gain more insight into the surgical aspects and complications 
of continuous intraperitoneal insulin infusion (CIPII) using an implantable pump.
Research frontiers
CIPII using an implantable pump improves glycaemic regulation in selected 
patients, compared to subcutaneous insulin infusion. In addition, if IP delivery 
could be linked to a kind of permanent sensor, and with a logarithm between 
this sensor and pump, a closed loop system could be created in the future. 
However, the complications and surgical experience with CIPII are important 
factors in the clinical use of CIPII.
Innovations and breakthroughs
The median operation-free period (OFP) for patients treated by CIPII with 
an implantable pump has been stable at 4.5 years over the last decade. 
Catheter occlusion (32.9%), pump dysfunction (17.1%), pain at the pump site 
(15.7%) and infections (10.0%) were the most frequent complications. Fifty re-
operations were performed due to complications, one per 5.6 patient years. No 
CIPII related mortality was reported. CIPII remains a safe treatment modality for 
specific patient groups. 
Applications
Knowledge of the complications of CIPII adds to patient counseling and clinical 
care. Since a new intraperitoneal insulin formulation had to be introduced in 
June 2011 as there were no batches of the original insulin formulation left, the 
findings of the present study should be taken into account when evaluating the 
effects associated with the use of the new insulin formulation. 
Terminology
Insulin delivered into the peritoneal space using an implantable pump. Insulin 
which is delivered into the peritoneal space is, to a large extent, absorbed di-
rectly (detectable within 1 h after administration) into the portal system, thereby 
mimicking the physiological route of insulin delivery from the pancreas. The 
time period between the initial operation and the first re-operation or, if patients 
have not experienced a re-operation, date of last follow up or death.
Peer review
The manuscript by van Dijk et al reports on the complications of CIPII in type 1 
diabetes. This study is an important addition to the literature, as it enumerates 
the complications of CIPII with a follow-up period of up to 12 years. In addition 
to providing data for the entire patient group, they also perform a subanalysis 
comparing patients starting CIPII between 2000-2007 and those starting from 
2007 onward. The current study provides longer follow-up of the patients who 
began CIPII in 2000 or later. This is most relevant to current care, as a pump 
battery with a longer life was introduced in 2000, as was a change in the insulin 
formulation used in the pump. 
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